Detailed explanation of the dosage form characteristics of brigatinib/brigatinib

Brigatinib is an oral drug that is a tyrosine kinase inhibitor. This drug is primarily used to treat a specific type of lung cancer, ALK-positive advanced or metastatic non-small cell lung cancer (NSCLC). Brigatinib can inhibit the growth and spread of cancer cells by blocking tyrosine kinase activity.

Brigatinib is available in tablet form, each tablet containing 30 mg or 90 mg of brigatinib. It can be taken orally and is usually recommended after meals. When patients received a single oral dose of brigatinib in the dose range of 30-240 mg, the average time for the drug to reach maximum plasma concentration was 1 to 4 hours. In studies of patients with advanced malignancies, brigatinib showed a linear relationship between plasma concentration and dose within the daily dose range of 60-240 mg. Specific dosage and duration will vary based on physician guidance and the patient's specific condition.

It should be noted that when using brigatinib to treat lung cancer, you should follow your doctor's recommendations and use it in accordance with the prescribed dosage and usage. At the same time, some side effects may occur during use, such as nausea, vomiting, diarrhea, fatigue, etc. If serious side effects or discomfort occur, the doctor should be informed in time.

In summary, brigatinib, as an oral tablet, provides a convenient and efficient treatment for patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer. At the same time, doctors also need to formulate personalized treatment plans based on the patient's specific conditions, pay close attention to changes in the patient's condition, and adjust drug dosage and treatment plans in a timely manner.